Sodium stibogluconate

Sodium stibogluconate
Clinical data
Trade namesPentostam, Stiboson, others[1]
AHFS/Drugs.comInternational Drug Names
Routes of
administration
intravenous, intramusclar[2]
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 2,4:2',4'-O-(oxydistibylidyne)bis[D-gluconic acid]
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
ECHA InfoCard100.170.909 Edit this at Wikidata
Chemical and physical data
FormulaC12H38Na3O26Sb2
Molar mass910.899 g·mol−1
3D model (JSmol)
  • [Na+].[Na+].[Na+].O=[Sb]2(O[Sb]1(=O)OC([C@H](O)CO)[C@H](O)[C@@H](O1)C([O-])=O)O[C@@H]([C@H](O)[C@@H](O2)C([O-])=O)[C@H](O)CO
  • InChI=1S/2C6H10O7.3Na.3O.2Sb/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;;;;;;;;/h2*2-5,7-8,10H,1H2,(H,12,13);;;;;;;;/q2*-2;3*+1;;;;2*+2/p-2/t2-,3?,4+,5-;2-,3-,4+,5-;;;;;;;;/m11......../s1 checkY
  • Key:RTLKTTNTVTVWPV-UQCYVGCHSA-L checkY
 ☒NcheckY (what is this?)  (verify)

Sodium stibogluconate, sold under the brand name Pentostam among others, is a medication used to treat leishmaniasis.[3] This includes leishmaniasis of the cutaneous, visceral, and mucosal types.[4] Some combination of miltefosine, paromomycin and liposomal amphotericin B, however, may be recommended due to issues with resistance.[2][5] It is given by injection.[6]

Side effects are common and include loss of appetite, nausea, muscle pains, headache, and feeling tired.[2][5] Serious side effect may include an irregular heartbeat or pancreatitis.[5] Sodium stibogluconate is less safe than some other options during pregnancy.[2] It is not believed to result in any problems if used during breastfeeding.[7] Sodium stibogluconate is in the pentavalent antimonials class of medication.[5]

Sodium stibogluconate has been studied as early as 1937 and has been in medical use since the 1940s.[8][9] It is on the World Health Organization's List of Essential Medicines.[10] In the United States, it is available from the Centers for Disease Control.[3]

  1. ^ "Sodium Stibogluconate". Drugs.com. Archived from the original on 20 December 2016. Retrieved 7 December 2016.
  2. ^ a b c d Organization, World Health (March 2010). Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases (PDF). World Health Organization. p. 55,186. hdl:10665/44412. ISBN 9789241209496. Archived (PDF) from the original on 2016-06-08.
  3. ^ a b "Our Formulary Infectious Diseases Laboratories CDC". www.cdc.gov. 22 September 2016. Archived from the original on 16 December 2016. Retrieved 7 December 2016.
  4. ^ Herwaldt BL, Berman JD (March 1992). "Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies". The American Journal of Tropical Medicine and Hygiene. 46 (3): 296–306. doi:10.4269/ajtmh.1992.46.296. PMID 1313656.
  5. ^ a b c d Oryan A, Akbari M (October 2016). "Worldwide risk factors in leishmaniasis". Asian Pacific Journal of Tropical Medicine. 9 (10): 925–932. doi:10.1016/j.apjtm.2016.06.021. PMID 27794384.
  6. ^ Joint Formulary Committee. "Sodium Stibogluconate". British National Formulary. BMJ Group and Pharmaceutical Press. Retrieved 29 December 2020.
  7. ^ "Sodium Stibogluconate use while Breastfeeding". Drugs.com. Archived from the original on 20 December 2016. Retrieved 7 December 2016.
  8. ^ Sneader W (2005). "Legacies of the Past: Chemical Medicines". Drug Discovery: A History. John Wiley & Sons. p. 58. ISBN 9780470015520. Archived from the original on 2016-12-20.
  9. ^ Jäger T, Koch O, Flohé L (2013). "Foreward". Trypanosomatid Diseases: Molecular Routes to Drug Discovery. John Wiley & Sons. p. 17. ISBN 9783527670406. Archived from the original on 2016-12-20.
  10. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search